Hosted by UCLA and the Pacific Heart, Lung and Blood Institute, the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma focused on research aimed at preserving vital lung function in MPM patients. Mesothelioma experts now agree that extrapleural pneumonectomy, which involves removal of the lung and surrounding diseased tissues, does not have a place in treatment of patients with this asbestos-related problem. Presentations included the latest surgical techniques for removal of cancerous tumors and a variety of adjunctive techniques.

Symposium leader, Robert B. Cameron, MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center, presented treatment strategies and results of multimodality treatment of patients with sarcomatoid-type MPM, the fastest spreading and most difficult to treat form of the disease. He also discussed current thermal research at UCLA and the effectiveness of cryoablation in killing MPM cancer cells.

The symposium’s distinguished faculty included Joseph S. Friedberg, MD, of the University of Pennsylvania, who presented promising new photodynamic therapy results using light to directly kill cancer cells; Olga Olevsky, MD, of UCLA Medical Center, who discussed results of a variety of novel treatment strategies; Italian Radiologist Marco Trovo, MD, who presented the early results of tomotherapy techniques following pleurectomy; and Raffit Hassan, MD, of the National Cancer Institute, who discussed anti-mesothelin agents for mesothelioma therapy.

“There were a number of incredibly exciting studies that far exceed what we’ve seen before,” said Dr. Cameron. “All of our collective efforts are finally beginning to pay off in new treatments that truly affect patients.”

This CME-granting event, which was held at the Sheraton Delfina Hotel, was attended by physicians, nurses, other medical professionals, as well as mesothelioma patients and others with an interest in advances in MPM treatments.

About The Pacific Meso Center

The Pacific Meso Center (PMC) is a division of the Pacific Heath, Lung & Blood Institute, a 501(c)3 nonprofit medical research institute established in 2002, which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related disease and informing them of their treatment options. PMC also connects newly diagnosed patients with patients that have been trough treatment and provides assistance and emotional support.

For further information, please contact:

Robert B. Cameron, M.D.  
Professor of Cardiothoracic Surgery and Surgical Oncology 
Director, UCLA Comprehensive Mesothelioma Program 
David Geffen School of Medicine at UCLA 
10780 Santa Monica Boulevard 
Suite 100 
Los Angeles, CA 90025-7613 
(310) 470-8980 (voice) 
(310) 470-3742 (fax) 
Email

Contact:  
Clare Cameron 
310-478-4678

By Patricia Kirk

An international roster of distinguished Mesothelioma (MPM) experts came together on Saturday, May 18, in Santa Monica, Calif., to discuss their latest research on lung-sparing therapies for MPM, a rare form of cancer that usually results from exposure to asbestos and commonly affects the pleura, or outer lining of the lungs, and chest wall.

Hosted by the Pacific Heart, Lung and Blood Institute and UCLA, the 3^rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma focused on research aimed at preserving vital lung function in mesothelioma patients. Presentations included the latest surgical techniques for removal of cancerous tumors and adjunct techniques and therapies to kill residual cancer cells following surgery and stop tumor growth.

A long-time advocate for lung-sparing pleurectomy/descortication surgery, Robert B. Cameron, MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center, opened the symposium with a presentation on timing of surgical treatment and techniques for safely removing tumors in patients with sarcomatoid-type mesothelioma. He noted that 10% to 15% of MPM cases involve sarcomatoid tumors, which are characteristically a sarcoma and involve a mesothelioma pseudocapsule (PC). “PC makes the surgery possible, but also makes surgery incomplete,” Dr. Camerson said, explaining that unlike epitheliod MPM, which remains localized, this cancer metastasizes quickly to other organs and tissues.

Joseph S. Friedberg, MD, BASc, Associate Professor and thoracic surgeon at the University of Pennsylvania, Hospital of Pennsylvania, Presbyterian Medical Center and Philadelphia VA Medical Center, presented a promising new photodynamic therapy (PDT) that uses light to directly kill residual cancer cells during surgery. “Experiments show that PDT is more effective in stopping tumor growth than chemotherapy,” he noted, suggesting that it may eventually replace chemotherapy follow-up after surgery, but further studies are required to verify its efficacy.

Olga Olevsky, MD, an oncologist at UCLA Medical Center, presented results of clinical trials on the effectiveness of adding the anti-VEGF (vascular endothelial growth factor) antibody to a combination of chemotherapy drugs to provoke immune response to VEGF, which occurs at high levels in mesothelioma patients, as well as a promising new vaccine for mesothelioma. “Mesothelioma resulting from asbestos exposure may have an immune mediated response,” she said, explaining that a phase II clinical trials with Tremelimumab, an anti-CTLA-4 (Cytotoxic T-lymphocyte-associated antigen 4) agent, blocks CTLA-4 activity, which suppresses immune response. “We’re excited about this agent,” said Olevsky, noting that of the 22 patients with advanced disease participating in the study, four achieved stable disease and the rest experienced an immune response that lasted six to nine months.

Raffit Hassan, MD, an oncologist and senior investigator in immunology at the National Cancer Institute, discussed anti-mesothelin agents for mesothelioma therapy.

Italian Radiologist Marco Trovo, MD, discussed a novel IG-IMRT (image-guided intensity-modulated radiotherapy) Helical Tomotherapy technique to effectively kill residual cancer cells post-operatively. A small pilot study involving 28 patients indicated that this approach allows safe delivery of high doses of radiation to the hemithorax of patients with intact lung and led to excellent loco-regional control and survival in MPM patients, he said. “Our data support the idea that this approach represents a concrete alternative to EPP (extrapleural pneumonectomy). EPP involves removal of the diseased lung, part of the pericardium (membrane covering the heart), part of the diaphragm (muscle between the lungs and the abdomen), and part of the parietal pleura (membrane lining the chest)–a procedure that a consensus of MPM experts contend is unnecessary and harms the patient.

Dr. Cameron, who also is Scientific Advisor for the Pacific Meso Center (PMC), delivered a presentation on current thermal therapy research at PMC and the effectiveness of hypothermia for improving, or potentially replacing chemotherapy, to kill residual microscopic disease following surgery. “Mesothelioma is particularly sensitive to cryoablation at temperatures below zero centigrade,” he said, noting that this therapy offers an intraoperative adjuvant therapy with acceptable toxicity.

Marko N. Kostic, PhD, a PMC biomedical engineer who is developing a novel device for treating Mesothelioma patients with hypothermia, discussed the challenges involved in designing a cryo-sprayer that uses liquid nitrogen to freeze cancerous tissue. He has developed three different spray nozzles to help the surgeon safely target the diseased area to a depth of one millimeter, while avoiding sensitive surrounding organs and structures. “It cycles three times to kill more cells, and then we’ll use adjuvant therapies to stimulate the immune system,” Kostic noted.

Raymond Wong, PhD, an immunology researcher at PMC, discussed creation of 3-D mesothelioma spheroid models to investigate altering of the mesothelioma microenvironment with cytokines (immunomodulating agents) to evoke immune response. Noting that research suggests that the immune system has a role in improving patient survival, Wong said, “The provocative idea is to tumor-target cytokine delivery.”

Michael J. Becich, MD, PhD., a pathologist who serves as Chairman of the University of Pittsburgh Department of Bioinformatics and on the National Mesothelioma Virtual Tissue Bank (NMVTB) Steering Committee, provided an update on the NMVTB, which now contains tissue microarrays (TMAs) of 1,200 MTM patients. The TMAs include DNA, blood, plasma and tissue. He explained how to query the system to find and request the appropriate biospecimens, which are available for free to the medical community. Noting that all the academic medical centers currently participating in the specimen bank are located on the East Coast, “ Becich said that NMVTB is planning to expand its reach nationwide and may establish a specimen collection center at PMC/UCLA under Dr. Cameron’s direction

“There were several, incredibly exciting studies coming out of this that far exceeds what we’ve seen before,” said Dr. Cameron. “These scientists translated information about treatment response in humans, which is totally unheard of in mesothelioma patients,” he added, noting that advancements are being made because people are now talking about it at scientific meetings. “All this effort is beginning to pay off finally, with treatments that affect patient care.”

This event, which was held at the Sheraton Delfina Hotel, was attended by physicians, nurses and other medical professionals, who received Continuing Medical Education credits, as well as mesothelioma patients and others with an interest in advances in MPM treatments.

Contact: Clare Cameron

310-478-4678

$150,000 Donation from Long-Time Supporter of Mesothelioma Research Helps Support The Pacific Meso Center’s 2013 Agenda

Los Angeles, CA. The Pacific Meso Center (PMC) is pleased to announce receipt of a generous donation from Roger G. Worthington of the Law Office of Worthington & Caron, P.C., a San Pedro, California-based law firm specializing in the representation of persons diagnosed with mesothelioma, a cancer caused by exposure to asbestos.

The $150,000 donation provides much-needed support for research into advancements in the diagnosis and treatment of mesothelioma being conducted at PMC’s laboratory in Los Angeles. The donation also supports three exciting programs that PMC will be presenting during the remainder of 2013 with other nonprofit organizations.

Worthington & Caron, P.C., will serve as the platinum sponsor for the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma, co-hosted by PMC and UCLA. “These funds will allow us to again convene an outstanding conference of world-renowned physicians and scientists leading the development of novel treatments that preserve the patient’s vital lung function,” said Robert Cameron, M.D., an internationally-recognized expert in mesothelioma who is again heading this year’s symposium. Dr. Cameron is Director of the UCLA Comprehensive Mesothelioma Program, Chief of Thoracic Surgery at the West Los Angeles VA Medical Center and one of PMC’s Scientific Advisors.

The Symposium reflects PMC’s two-fold mission as a research facility dedicated to finding lung-sparing treatments for pleural mesothelioma, and as a patient advocacy center to help patients obtain urgently-needed assistance in their everyday lives. With a CME-accredited curriculum, the Symposium provides education about the latest advancements in the field for doctors and scientists on the front lines of mesothelioma medicine, and also provides patients, families and caregivers with valuable resources to help them make informed decisions about their treatment. The 2013 Symposium will be held on Saturday May 18th at the Sheraton Delfina Hotel in Santa Monica, California. [ http://pacificmesocenter.org/2013/03/mesothelioma-experts-to-meet-for-3rd-international-symposium-on-lung-sparing-therapies-for-malignant-pleural-mesothelioma-may-18th/ ]

Worthington & Caron, P.C. will also serve as Title Sponsor for “The Greatest Escape Motorcycle Rally”. This first-ever event is a memorial ride to celebrate the 50th anniversary of the Great Escape film, starring Steve McQueen, who lost his battle to mesothelioma in 1980. The event will take place on Sunday, September 22nd featuring an escorted motorcycle ride from Bartel’s Harley Davidson, Marina Del Rey, CA to Sycamore Cove State Beach in Malibu.

Finally, Worthington & Caron, P.C. will serve as the Platinum Sponsor for the 2^nd Annual 5K Walk/Hike for Meso at the Paramount Ranch in Agoura Hills. Last year’s event featured 150 dedicated walkers and hikers who enjoyed a brisk trail walk/hike followed by a western barbeque with entertainment and raised a total of $67,000. This year’s event will take place on Sunday, October 27^th once again at the Paramount Ranch.

All proceeds from The Greatest Escape Motorcycle Rally and the 5K Walk/Hike for Meso will support PMC’s research into lung-sparing therapies for pleural mesothelioma.

PMC thanks Worthington & Caron, P.C. for their continued support. Worthington & Caron, P.C. has been an industry leader in funding mesothelioma research for nearly twenty years. The Punch Worthington Laboratory at UCLA’s David Geffen School of Medicine was established in honor of attorney Roger Worthington’s father, David “Punch” Worthington, Ph.D, who passed away from asbestos-related lung cancer in 2006.

About The Pacific Meso Center

The Pacific Meso Center (PMC) is a specialized Center for mesothelioma within the division of lung research for PHLBI, a 501(c)(3) non-profit medical research institute established in 2002 and which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options. PMC also connects newly diagnosed patients with patients who have undergone treatment and provides assistance and emotional support.  For further information call 1-888-996-MESO, or visit our website at www.pacificmesocenter.org.

Accounting Director at Los Angeles’  PrepareYourBooks.com Brings Her Accounting Expertise to Fight Mesothelioma

Los Angeles, CA. March 20, 2013/- The Pacific Meso Center (PMC) at the Pacific Heart, Lung & Blood Institute (PHLBI) (http://pacificmesocenter.org/) is pleased to announce it has added Anu Venkatesh to its board of directors as Treasurer.  Anu is a Director of Accounting at PrepareYourBooks.com (http://www.prepareyourbooks.com/), an accounting and financial management firm in Glendale, California that provides accounting services to individuals, corporations and non-profit organizations.

“Anu stepped right up to the plate on our Inaugural 5K Walk/Hike last October in Agoura Hills, and contributed enormously to our success”, said Clare Cameron, Executive Director of PMC.  “We are most fortunate to have her on our team.”

At PrepareYourBooks.com,  Anu is responsible for the oversight of portfolio management for all client accounts. Her accounting experience includes the preparation of financial statements, tax returns, complex financial budgets and personal financial statements for individuals, partnerships, corporations and LLC’s.  Anu started her career in 1997 in India, where she was an executive accountant at an export company.   She is a member of the Institute of Chartered Accountants in her home country and is taking continuing education on obtaining her Certified Public Accountant Certificate in California.

“I’m excited to be able to contribute to this organization.  My passion is to help the community and mesothelioma research is a great cause for which to raise funds and awareness,” Anu commented upon accepting the invitation to join the board. “It’s an honor to work with Dr. Cameron and his team to help share the progress he has made toward the life extending management of this disease.  Although the general public sees the ads from law firms everyday regarding mesothelioma, very few understand the terrible toll it has in our community.  PMC is an organization that makes a difference by actually being in the trenches with cutting edge research while providing vital emotional and educational support and hope to the victims and their families”.

“Anu brings insight, passion and expertise in the financial realm and we are very pleased to have her on board as PMC moves forward in our fight to defeat mesothelioma,” said Hal Lieberman, Chairman of the board of PHLBI.

About The Pacific Meso Center:

The Pacific Meso Center (PMC) is a division of the Pacific Heart, Lung & Blood Institute, a 501(c)(3) non-profit medical research institute established in 2002 which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM).  The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs.  PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options.  PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

For further information please contact:

Clare Cameron

310-478-4678

ccameron@phlbi.org.

www.pacificmesocenter.org

The Pacific Meso Center, Los Angeles, CA:  Mesothelioma experts will gather on Saturday, May 18^th 2013 for the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma at the Sheraton Delfina in Santa Monica, CA.  Dr. Robert B. Cameron, M.D., Director of the UCLA Mesothelioma Comprehensive Research Program, Chief of Thoracic Surgery at the West Los Angeles VA Medical Center and Scientific Advisor at Pacific Meso Center (http://pacificmesocenter.org/) will again lead this year’s symposium.  Dr. Cameron has been a leading proponent of lung-sparing pleurectomy/decortication (P/D) surgical procedures for malignant pleural mesothelioma for nearly 20 years.

This year’s meeting will include distinguished faculty and experts from prestigious universities such as UCLA, University of Pennsylvania, University of Pittsburg, National Institutes of Health and Centro di Riferimento Oncologico CRO-Aviano in Italy.  While the seminar is primarily designed for physicians and offers continuing medical education (CME) credit, it’s also open to physicians in training, nurses, mesothelioma victims, their families, students, and other interested parties.

At the 1^st and 2nd annual International Symposia, specialists concluded that if surgical treatment was to be performed at all, the preferred treatment is the pleurectomy decortication (P/D) over the more radical extra-pleural pneumonectomy (EPP) surgery. P/D is an operation for mesothelioma that removes the involved pleura and frees the underlying lung so that it can expand and fill the pleural cavity, whereas EPP surgery involves the removal of the lung along with its coverings and the associated coverings of the heart, diaphragm and pericardium.

“Once again, this symposium highlights the best research and thinking by bringing the preeminent scientific and medical minds from around the world that are advancing the treatment of mesothelioma,” said Dr. Cameron. “Research and practice over the past several years have continued to evolve working to improve cancer outcomes without unnecessarily sacrificing the affected lung. Clearly, it is best for the patient to treat mesothelioma as a chronic illness while preserving the function of both lungs,” he added.

The Worthington Caron Law Firm (http://mesothel.com/) is once again sponsoring the symposium for $50,000 as a Platinum sponsor. Gold sponsors at $15,000 are Napoli Bern (http://www.napolibern.com/) and Simons Greenstone Panatier and Bartlett (http://www.sgpblaw.com/). “The generosity of our sponsors enables us to continue to provide the most up to date information on treatment and therapies to the medical community. The information allows mesothelioma sufferers and their family members to make sound decisions as to their best treatment options ” said Clare Cameron, Executive Director of PMC.

Early Bird tickets can be purchased before May 3^rd online at www.cme.ucla.edu/courses.

For more information, please contact UCLA at 310-794-2620 or call Clare Cameron at the Pacific Meso Center at Pacific Heart, Lung, Blood Institute at 310-478-4678.

http//www.pacificmesocenter.org

##########

LOS ANGELES, Feb. 13, 2013 /PRNewswire/ – The Pacific Meso Center (PMC) gratefully acknowledges the generous pledge of $500,000 from the family of John Johnson, a military veteran who passed away from malignant pleural mesothelioma (MPM).  John Johnson’s story and his horrific treatment by the U.S. legal system during his asbestos lawsuit which led to his early demise were chronicled by Michael Hiltzik in a Los Angeles Time’s article (http://articles.latimes.com/2012/apr/22/business/la-fi-hiltzik-20120422). Instead of being angry, the family is now challenging others, particularly attorneys involved in asbestos litigation to donate to PMC. The Johnsons will match such donations up to $500,000 thereby creating a $1 million fund which will be used for a collaborative research program with the Department of Veterans Affairs.

Mesothelioma is a diffuse and aggressive cancerof the chest lining (pleura) that is strongly associated with exposure to asbestos. Over one-third of the approximately 3,000 Americans who are diagnosed with mesothelioma each year served in the U.S. military.

“We want to help other families get diagnosed as early as possible, so that patients have a fighting chance to survive,” said Sue Johnson, widow of John Johnson. Her pledge was prompted in part by the care her husband received at the VA. “Dr. Robert B. Cameron did everything he could surgically to save John, but by the time he was diagnosed, he was already stage III.”

The Johnson family is hopeful that their pledge will jump-start the proposed Admiral Zumwalt Comprehensive Mesothelioma Research and Treatment Program at the VA. The program’s name-sake, Admiral Elmo Zumwalt, the United States’ Chief Naval Officer from 1970 to 1974, was exposed to asbestos while serving on Navy ships and passed away from MPM in 2001. The Admiral Zumwalt Comprehensive Mesothelioma Research and Treatment Program would be located within the West Los Angeles VA Medical Center.

PMC works in collaboration with doctors at the West Los Angeles VA and UCLA Medical Centers, who have extensive experience in treating this malady, to develop significant advancements in the diagnosis and treatment of MPM.  PMC’s scientific advisor, Dr. Robert B. Cameron, has been treating MPM patients for over 20 years.  He focuses on treatments which “spare” the lung and treat MPM as a chronic disease.  Dr. Cameron will be chairing the 3rd International Symposium on Lung-Sparing Therapies on Saturday, May 18th, 2013 at the Sheraton Delfina Hotel in Santa Monica, CA.

“The Johnson family’s generosity is truly amazing,” said PMC Executive Director Clare Cameron of the pledge.   “We would hope that the many law firms involved in the field of mesothelioma litigation, will do the right thing and step forward to match this funding and spur this initiative forward.  Their contribution will help with the development of the new center and greatly improve the way veterans are diagnosed and treated for MPM at the VA.”

About The Pacific Meso Center:

The Pacific Meso Center (PMC) is a division of the Pacific Heart, Lung & Blood Institute, a 501(c)(3) non-profit medical research institute established in 2002 which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options. PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

For further information please contact:
Clare Cameron
310-478-4678
ccameron@phlbi.org
www.pacificmesocenter.org

PMC scientists also are beginning to study gene expression in mesothelioma cells; that is, the extent to which certain genetic signals are abnormally increased or decreased compared to normal cells.  Cell growth and death is highly regulated by genetic signals, and a better understanding of the specific genetic changes that occur in mesothelioma cells will give us insight into what causes these cells to grow and divide uncontrollably.  Furthermore, the specific genes involved may provide a characteristic genetic profile or signature, which may be used to identify individuals who are at particularly high risk for developing mesothelioma even years before it occurs.  Such knowledge would allow treatments to be tested that potentially could prevent the disease altogether.

Contact:  Clare Cameron

Executive Director

310-478-4678

 The Pacific Meso Center Appoints Savannah Cline, RN as Medical Liaison.

Newly created Medical Liaison position to develop comprehensive educational system for mesothelioma patients

Los Angeles, CA.  The Pacific Meso Center (PMC) is pleased to announce the appointment of Savannah Cline, RN, BSN, to the newly created position of Medical Liaison. Her mission will be to develop a comprehensive educational system that will enhance PMC’s outreach services for patients with mesothelioma, an asbestos-related disease.

 “Savannah is the perfect choice for this position,” said Dr. Robert B. Cameron, a cardiothoracic surgeon and surgical oncologist, who is a scientific advisor at the PMC. “Ms. Cline’s hospital bedside experience, which includes chest diseases, surgery, and critical care, as well as her keen understanding of our mission, social media and potential mesothelioma resources will be the cornerstone of our outreach program’s efforts to educate the public about this disease.”

 “Ms. Cline will be an indispensable resource for mesothelioma patients, as well as their families and friends who are searching for information and a better understanding of mesothelioma as a disease as well as the most current treatment options, social issues, and support,” Dr. Cameron continued, noting the proliferation of websites offering confusing and out-of-date medical information.

 Ms. Cline’s duties will include educating the public about all mesothelioma issues, such as risk factors, symptoms, diagnostic testing, screening, existing treatments, available patient and family support, clinical trials as well as possible future therapies and advances.

 She will also develop a comprehensive internet-based educational system, including webinars, blogs and website content and she will lead PMC’s development of a “mesothelioma” social media presence.  Additionally, Ms. Cline will develop an online support network for mesothelioma patients and their families to help guide them through the disease process.

 Ms. Cline obtained her Bachelor in Nursing from Indiana State University, College of Nursing, Health and Human Services in Terre Haute, Indiana.  Prior to joining PMC she worked as an RN on the Cardiothoracic Intensive Care Unit at Children’s Hospital in Los Angeles.

 In addition to his role at the PMC, Dr. Cameron is the director of the UCLA Comprehensive Mesothelioma Program of the David Geffen School of Medicine at UCLA and the Chief of Thoracic Surgery at the West Los Angeles Veterans’ Administration Medical Center.

 About The Pacific Meso Center:

The Pacific Meso Center (PMC) is a division of the Pacific Heart, Lung & Blood Institute, a 501(c)(3) non-profit medical research institute established in 2002 which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM).  The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs.  PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options.  PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

 For further information please contact:

Clare Cameron

310-478-4678

ccameron@phlbi.org.

www.pacificmesocenter.org